AU Patent

AU2007217770B2 — New crystal forms and pharmaceutical compositions of (+) -R-zileuton

Assigned to Chiesi USA Inc · Expires 2011-09-08 · 15y expired

What this patent protects

Crystalline forms of (+)-R-zileuton, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (&…

USPTO Abstract

Crystalline forms of (+)-R-zileuton, which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of (+)-R-zileuton are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline (+)-R-zileuton, and using it to inhibit 5-lipoxygenase activity in subjects to treat a number of diseases, are also discussed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2007217770B2
Jurisdiction
AU
Classification
—
Expires
2011-09-08
Drug substance claim
No
Drug product claim
No
Assignee
Chiesi USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.